Daniel Jenkin
Daniel Jenkin
MBChB, MSc, DTM&H, MRCP
CLINICAL RESEARCH FELLOW
Recent publications
-
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial
Jenkin D. et al, (2025), The Lancet Microbe, 101022 - 101022
-
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Conlin K. et al, (2025), Vaccine, 45, 126582 - 126582
-
Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK.
Borthwick N. et al, (2024), The Lancet. Microbe
-
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Satti I. et al, (2024), The Lancet Infectious Diseases
-
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964